biostudies-literatureValenti LMinistero della SaluteFondazione IRCCS Ca&apos; Granda Ospedale Maggiore PoliclinicoEuropean CommissionGilead Sciences867-877https://www.ebi.ac.uk/biostudies/studies/S-EPMC8948549biostudies-literatureUnknown6(4)The aim of this study was to examine the impact of features of dysmetabolism on liver disease severity, evolution, and clinical outcomes in a real-life cohort of patients treated with direct acting antivirals for chronic hepatitis C virus (HCV) infection. To this end, we considered 7,007 patients treated between 2014 and 2018, 65.3% with advanced fibrosis, of whom 97.7% achieved viral eradication (NAVIGATORE-Lombardia registry). In a subset (n = 748), liver stiffness measurement (LSM) was available at baseline and follow-up. Higher body mass index (BMI; odds ratio [OR] 1.06 per kg/m² , 1.03-1.09) and diabetes (OR 2.01 [1.65-2.46]) were independently associated with advanced fibrosis at baseline, whereas statin use was protective (OR 0.46 [0.35-0.60]; P < 0.0001 for all). The impHepatology communicationsDysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study.PMC8948549Gilead Fellowship 2018 ItalyPR‐0391RC100017A777377CV PREVITALRF‐2016‐02364358Gilead_IN‐IT‐989‐5790101016726Terreni NPelusi SD'Ambrosio RD'Arminio Monforte AZuccaro VColombo MCValenti LFagiuoli SDegasperi EPan ALorini GBuscarini ERumi MGAghemo APrati DQuirino TBonfanti PLampertico PPasulo LMemoli MSpinetti ABianco CCarriero CMendeni MGritti SRe TIegri CAutolitano APuoti MSoria ACologni GDel Poggio PSpinelli OGiorgini AAimo GNAVIGATORE-Lombardia NetworkPigozzi MGVigano MColombo MCarderi IMenzaghi BfalseDysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study.The aim of this study was to examine the impact of features of dysmetabolism on liver disease severity, evolution, and clinical outcomes in a real-life cohort of patients treated with direct acting antivirals for chronic hepatitis C virus (HCV) infection. To this end, we considered 7,007 patients treated between 2014 and 2018, 65.3% with advanced fibrosis, of whom 97.7% achieved viral eradication (NAVIGATORE-Lombardia registry). In a subset (n = 748), liver stiffness measurement (LSM) was available at baseline and follow-up. Higher body mass index (BMI; odds ratio [OR] 1.06 per kg/m² , 1.03-1.09) and diabetes (OR 2.01 [1.65-2.46]) were independently associated with advanced fibrosis at baseline, whereas statin use was protective (OR 0.46 [0.35-0.60]; P < 0.0001 for all). The imp2022-01-01T00:00:00Z2022 Apr2025-04-05T14:43:30.627Z2025-04-05T14:43:30.627ZS-EPMC89485493481194910.1002/hep4.1851